This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Neuro-focused Biohaven Pharmaceutical Holding Co. Ltd. netted $303mm in a public offering of 7.5mm shares (including partial exercise of the overallotment) at $43. The company will use the proceeds to support continued and expanded development of its three platforms: calcitonin gene-related peptide (CGRP) receptor antagonists; glutamate modulators; and myeloperoxidase (MPO) inhibitors. An NDA submission is expected in mid-2019 for its most advanced CGRP candidate rimegepant (in Phase III for migraine) using a priority review voucher (PRV) Biohaven bought earlier this year from GW Pharmaceuticals, allowing the former to designate a single NDA for priority status and providing an accelerated six-month review period.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?